Deferasirox and Deferoxamine
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cardiac Iron Overload
Conditions
Cardiac Iron Overload
Trial Timeline
Jan 1, 2011 → Nov 1, 2013
NCT ID
NCT01254227About Deferasirox and Deferoxamine
Deferasirox and Deferoxamine is a phase 2 stage product being developed by Novartis for Cardiac Iron Overload. The current trial status is completed. This product is registered under clinical trial identifier NCT01254227. Target conditions include Cardiac Iron Overload.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01254227 | Phase 2 | Completed |
Competing Products
20 competing products in Cardiac Iron Overload